Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Agence France Presse (12.16.07):P. Parameswaran - Monday, December 17, 2007
The landmark study released last week is the first to capture the economic benefits of the World Health Organization's revised DOTS (directly observed therapy, short-course) strategy proposed in WHO's Global Plan to Stop TB covering the 2006-15 period. WHO first introduced DOTS in the 1990s, but the increase in HIV cases and the rise of drug resistance over the years have caused the strategy to be revamped.
"These Asian nations have to grapple with a $1.17 trillion economic cost over a 10 year period if TB prevention and control are sustained at current levels of treatment," said Ramanan Laxminarayan, an economist and lead author of the study. "But if they embrace WHO's global plan they could collectively save about $10 billion each year or $100 billion during the 10-year period. However, the costs of the global plan may be greater than these benefits in some countries."
The study covered 22 high-burden countries, including China, India, Indonesia, Philippines, Thailand, Afghanistan, Bangladesh, Cambodia, Myanmar, Pakistan, and Vietnam. These 11 Asian nations accounted for 1 million of the 1.7 million TB deaths in the 22 countries studied, Laxminarayan said.
Among these countries, the economic impact of TB deaths and the benefits of TB control are greatest in China and India, where rising incomes and a relatively high number of TB deaths are combining to create a significant economic effect, the study found.
071217
AD072623
Copyright © 2007 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.